Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	estrogen catabolic process	UGT1A8 UGT1A7 UGT1A9	2.90e-06	5	138	3	GO:0006711
GeneOntologyBiologicalProcess	flavonoid glucuronidation	UGT1A8 UGT1A7 UGT1A9	2.90e-06	5	138	3	GO:0052696
GeneOntologyBiologicalProcess	phenylpropanoid catabolic process	UGT1A8 UGT1A7 UGT1A9	5.78e-06	6	138	3	GO:0046271
GeneOntologyBiologicalProcess	coumarin catabolic process	UGT1A8 UGT1A7 UGT1A9	5.78e-06	6	138	3	GO:0046226
GeneOntologyBiologicalProcess	flavone metabolic process	UGT1A8 UGT1A7 UGT1A9	5.78e-06	6	138	3	GO:0051552
GeneOntologyBiologicalProcess	multi-pass transmembrane protein insertion into ER membrane	NOMO1 NOMO2 NOMO3	2.39e-05	9	138	3	GO:0160063
GeneOntologyBiologicalProcess	phenylpropanoid metabolic process	UGT1A8 UGT1A7 UGT1A9	3.40e-05	10	138	3	GO:0009698
GeneOntologyBiologicalProcess	coumarin metabolic process	UGT1A8 UGT1A7 UGT1A9	3.40e-05	10	138	3	GO:0009804
GeneOntologyBiologicalProcess	xenobiotic glucuronidation	UGT1A8 UGT1A7 UGT1A9	6.17e-05	12	138	3	GO:0052697
GeneOntologyBiologicalProcess	flavonoid metabolic process	UGT1A8 UGT1A7 UGT1A9	7.98e-05	13	138	3	GO:0009812
GeneOntologyBiologicalProcess	smooth endoplasmic reticulum calcium ion homeostasis	APP DMTN	1.33e-04	3	138	2	GO:0051563
GeneOntologyCellularComponent	multi-pass translocon complex	NOMO1 NOMO2 NOMO3	2.50e-05	9	142	3	GO:0160064
GeneOntologyCellularComponent	ER membrane insertion complex	NOMO1 NOMO2 NOMO3	1.06e-04	14	142	3	GO:0072379
GeneOntologyCellularComponent	myosin II filament	MYH10 MYH14	1.37e-04	3	142	2	GO:0097513
GeneOntologyCellularComponent	I-kappaB/NF-kappaB complex	NFKB1 NFKB2	2.72e-04	4	142	2	GO:0033256
GeneOntologyCellularComponent	main axon	ANK3 MAP2 SPOCK1 APP CRHR2	3.54e-04	89	142	5	GO:0044304
GeneOntologyCellularComponent	myosin complex	MYH10 MYO1E MYO7B MYH14	6.95e-04	59	142	4	GO:0016459
Domain	DUF2012	NOMO1 NOMO2 NOMO3	1.57e-06	4	138	3	PF09430
Domain	DUF2012	NOMO1 NOMO2 NOMO3	1.57e-06	4	138	3	IPR019008
Domain	Carb-bd-like_fold	NOMO1 NOMO2 NOMO3	2.15e-05	8	138	3	IPR013784
Domain	CarboxyPept_regulatory_dom	NOMO1 NOMO2 NOMO3	1.07e-04	13	138	3	IPR014766
Domain	-	NOMO1 NOMO2 NOMO3	1.07e-04	13	138	3	2.60.40.1120
Domain	LIM3_prickle	PRICKLE1 PRICKLE2	1.62e-04	3	138	2	IPR033727
Domain	LIM2_prickle	PRICKLE1 PRICKLE2	1.62e-04	3	138	2	IPR033726
Domain	PET_prickle	PRICKLE1 PRICKLE2	1.62e-04	3	138	2	IPR033723
Domain	Myosin_head_motor_dom	MYH10 MYO1E MYO7B MYH14	1.73e-04	38	138	4	IPR001609
Domain	MYOSIN_MOTOR	MYH10 MYO1E MYO7B MYH14	1.73e-04	38	138	4	PS51456
Domain	Myosin_head	MYH10 MYO1E MYO7B MYH14	1.73e-04	38	138	4	PF00063
Domain	MYSc	MYH10 MYO1E MYO7B MYH14	1.73e-04	38	138	4	SM00242
Domain	Post-SET_dom	KMT2B SUV39H2 SETDB1	2.06e-04	16	138	3	IPR003616
Domain	PostSET	KMT2B SUV39H2 SETDB1	2.06e-04	16	138	3	SM00508
Domain	POST_SET	KMT2B SUV39H2 SETDB1	2.06e-04	16	138	3	PS50868
Domain	CarboxyPept-like_regulatory	NOMO1 NOMO2 NOMO3	2.49e-04	17	138	3	IPR008969
Domain	UDPGT	UGT1A8 UGT1A7 UGT1A9	4.76e-04	21	138	3	PF00201
Domain	UDPGT	UGT1A8 UGT1A7 UGT1A9	4.76e-04	21	138	3	PS00375
Domain	UDP_glucos_trans	UGT1A8 UGT1A7 UGT1A9	4.76e-04	21	138	3	IPR002213
Domain	IPT_NFkappaB	NFKB1 NFKB2	5.34e-04	5	138	2	IPR033926
Domain	RHD_CS	NFKB1 NFKB2	5.34e-04	5	138	2	IPR030492
Domain	Sushi	PAPPA2 CFHR4 SUSD1 CSMD1	5.87e-04	52	138	4	PF00084
Domain	CCP	PAPPA2 CFHR4 SUSD1 CSMD1	6.78e-04	54	138	4	SM00032
Domain	SUSHI	PAPPA2 CFHR4 SUSD1 CSMD1	7.78e-04	56	138	4	PS50923
Domain	Xpo1	IPO13 XPOT	7.97e-04	6	138	2	PF08389
Domain	PET	PRICKLE1 PRICKLE2	7.97e-04	6	138	2	PF06297
Domain	PET_domain	PRICKLE1 PRICKLE2	7.97e-04	6	138	2	IPR010442
Domain	PET	PRICKLE1 PRICKLE2	7.97e-04	6	138	2	PS51303
Domain	WxxW_domain	MUC5B CEMIP	7.97e-04	6	138	2	IPR025155
Domain	Mucin2_WxxW	MUC5B CEMIP	7.97e-04	6	138	2	PF13330
Domain	Exportin-1/Importin-b-like	IPO13 XPOT	7.97e-04	6	138	2	IPR013598
Domain	Sushi_SCR_CCP_dom	PAPPA2 CFHR4 SUSD1 CSMD1	8.32e-04	57	138	4	IPR000436
Domain	TUDOR	PHF20 SETDB1 KDM4B	1.01e-03	27	138	3	SM00333
Domain	DEATH	ANK3 NFKB1 NFKB2	1.01e-03	27	138	3	SM00005
Domain	Pre-SET	SUV39H2 SETDB1	1.11e-03	7	138	2	PF05033
Domain	Notch_dom	PAPPA2 GNPTAB	1.11e-03	7	138	2	IPR000800
Domain	PreSET	SUV39H2 SETDB1	1.11e-03	7	138	2	SM00468
Domain	Notch	PAPPA2 GNPTAB	1.11e-03	7	138	2	PF00066
Domain	Pre-SET_dom	SUV39H2 SETDB1	1.11e-03	7	138	2	IPR007728
Domain	NL	PAPPA2 GNPTAB	1.11e-03	7	138	2	SM00004
Domain	PRE_SET	SUV39H2 SETDB1	1.11e-03	7	138	2	PS50867
Domain	VWC	VWF MUC5B PXDNL	1.13e-03	28	138	3	PF00093
Domain	-	PAPPA2 FLNA VSIG4 NOMO1 IGSF10 HMCN1 NOMO2 PXDNL NFKB1 NFKB2 TREM1 FGFR2 NOMO3	1.28e-03	663	138	13	2.60.40.10
Domain	Tudor	PHF20 SETDB1 KDM4B	1.38e-03	30	138	3	IPR002999
Domain	Alkaline_phosphatase_core	ENPP6 ARSJ ARSI	1.52e-03	31	138	3	IPR017850
Domain	Alkaline_Pase-like_a/b/a	ENPP6 ARSJ ARSI	1.52e-03	31	138	3	IPR017849
Domain	-	ENPP6 ARSJ ARSI	1.52e-03	31	138	3	3.40.720.10
Domain	Death	ANK3 NFKB1 NFKB2	1.83e-03	33	138	3	PF00531
Domain	Copine	CPNE4 CPNE7	1.89e-03	9	138	2	PF07002
Domain	Copine	CPNE4 CPNE7	1.89e-03	9	138	2	IPR010734
Domain	IQ	MYH10 MYO1E MYO7B MYH14	1.89e-03	71	138	4	PF00612
Domain	-	VWF HMCN1 CPNE4 CPNE7	2.20e-03	74	138	4	3.40.50.410
Domain	Ig-like_fold	PAPPA2 FLNA VSIG4 NOMO1 IGSF10 HMCN1 NOMO2 PXDNL NFKB1 NFKB2 TREM1 FGFR2 NOMO3	2.23e-03	706	138	13	IPR013783
Domain	RHD_dimer	NFKB1 NFKB2	2.35e-03	10	138	2	IPR032397
Domain	RHD_dimer	NFKB1 NFKB2	2.35e-03	10	138	2	PF16179
Domain	REL_1	NFKB1 NFKB2	2.35e-03	10	138	2	PS01204
Domain	-	NFKB1 NFKB2	2.35e-03	10	138	2	2.60.40.340
Domain	NFkB/Dor	NFKB1 NFKB2	2.35e-03	10	138	2	IPR000451
Domain	RHD_DNA_bind_dom	NFKB1 NFKB2	2.35e-03	10	138	2	IPR011539
Domain	RHD_DNA_bind	NFKB1 NFKB2	2.35e-03	10	138	2	PF00554
Domain	REL_2	NFKB1 NFKB2	2.35e-03	10	138	2	PS50254
Domain	VWFC_1	VWF MUC5B PXDNL	2.36e-03	36	138	3	PS01208
Domain	VWFC_2	VWF MUC5B PXDNL	2.76e-03	38	138	3	PS50184
Domain	Death_domain	ANK3 NFKB1 NFKB2	2.76e-03	38	138	3	IPR000488
Domain	VWC	VWF MUC5B PXDNL	2.76e-03	38	138	3	SM00214
Domain	DEATH_DOMAIN	ANK3 NFKB1 NFKB2	2.76e-03	38	138	3	PS50017
Domain	GFP-like	HMCN1 SUSD1	2.85e-03	11	138	2	IPR023413
Domain	-	HMCN1 SUSD1	2.85e-03	11	138	2	2.40.155.10
Domain	C2	PLA2G4E PRKCG CPNE4 FER1L5 CPNE7	2.90e-03	131	138	5	PF00168
Domain	VWFA	VWF HMCN1 CPNE4 CPNE7	3.20e-03	82	138	4	PS50234
Domain	C8	VWF MUC5B	3.41e-03	12	138	2	PF08742
Domain	TIL	VWF MUC5B	3.41e-03	12	138	2	PF01826
Domain	SET	KMT2B SUV39H2 SETDB1	3.43e-03	41	138	3	PF00856
Domain	VWA	VWF HMCN1 CPNE4 CPNE7	3.49e-03	84	138	4	SM00327
Domain	C2	PLA2G4E PRKCG CPNE4 FER1L5 CPNE7	3.51e-03	137	138	5	SM00239
Domain	VWF_dom	VWF MUC5B PXDNL	3.67e-03	42	138	3	IPR001007
Domain	Unchr_dom_Cys-rich	VWF MUC5B	4.01e-03	13	138	2	IPR014853
Domain	C8	VWF MUC5B	4.01e-03	13	138	2	SM00832
Domain	C2	PLA2G4E PRKCG CPNE4 FER1L5 CPNE7	4.09e-03	142	138	5	PS50004
Domain	IQ_motif_EF-hand-BS	MYH10 MYO1E MYO7B MYH14	4.46e-03	90	138	4	IPR000048
Domain	TIL_dom	VWF MUC5B	4.65e-03	14	138	2	IPR002919
Domain	SET	KMT2B SUV39H2 SETDB1	4.75e-03	46	138	3	SM00317
Domain	-	PLA2G4E PRKCG CPNE4 FER1L5 CPNE7	4.87e-03	148	138	5	2.60.40.150
Domain	IQ	MYH10 MYO1E MYO7B MYH14	5.01e-03	93	138	4	PS50096
Domain	Myosin_N	MYH10 MYH14	5.34e-03	15	138	2	PF02736
Domain	IBN_N	IPO13 XPOT	5.34e-03	15	138	2	PF03810
Domain	Myosin_N	MYH10 MYH14	5.34e-03	15	138	2	IPR004009
Domain	CUB	DCBLD1 CSMD1 TMPRSS7	5.67e-03	49	138	3	PF00431
Domain	SET_dom	KMT2B SUV39H2 SETDB1	6.00e-03	50	138	3	IPR001214
Domain	SET	KMT2B SUV39H2 SETDB1	6.00e-03	50	138	3	PS50280
Domain	CUB	DCBLD1 CSMD1 TMPRSS7	6.00e-03	50	138	3	SM00042
Domain	Growth_fac_rcpt_	ERBB3 LAMA3 FBN1 HMCN1 SUSD1	6.07e-03	156	138	5	IPR009030
Domain	VWF_type-D	VWF MUC5B	6.08e-03	16	138	2	IPR001846
Domain	IBN_N	IPO13 XPOT	6.08e-03	16	138	2	SM00913
Domain	VWFD	VWF MUC5B	6.08e-03	16	138	2	PS51233
Domain	VWD	VWF MUC5B	6.08e-03	16	138	2	SM00216
Domain	Sulfatase_CS	ARSJ ARSI	6.08e-03	16	138	2	IPR024607
Domain	VWD	VWF MUC5B	6.08e-03	16	138	2	PF00094
Domain	VWF_A	VWF HMCN1 CPNE4 CPNE7	6.25e-03	99	138	4	IPR002035
Domain	-	DCBLD1 CSMD1 TMPRSS7	6.70e-03	52	138	3	2.60.120.290
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	KMT2B SUV39H2 SETDB1 NFKB1 NFKB2	2.35e-05	46	106	5	MM14933
Pathway	WP_FGF23_SIGNALING_IN_HYPOPHOSPHATEMIC_RICKETS_AND_RELATED_DISORDERS	GALNT3 NFKB1 NFKB2 FGFR2	2.40e-05	23	106	4	M39862
Pathway	WP_GLUCURONIDATION	UGT1A8 UGT1A7 UGT1A9 PGM2	3.38e-05	25	106	4	MM15820
Pathway	WP_GLUCURONIDATION	UGT1A8 UGT1A7 UGT1A9 PGM2	3.97e-05	26	106	4	M39404
Pathway	KEGG_STARCH_AND_SUCROSE_METABOLISM	UGT1A8 UGT1A7 UGT1A9 AGL PGM2	4.29e-05	52	106	5	M14171
Pathway	WP_INCLUSION_BODY_MYOSITIS	APP NFKB1 NFKB2	6.53e-05	11	106	3	M42545
Pathway	REACTOME_TRAF6_MEDIATED_NF_KB_ACTIVATION	APP NFKB1 NFKB2	1.42e-04	14	106	3	MM15641
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	KMT2B SUV39H2 SETDB1 NFKB1 NFKB2	1.79e-04	70	106	5	M27231
Pathway	REACTOME_THE_NLRP3_INFLAMMASOME	APP NFKB1 NFKB2	2.16e-04	16	106	3	M1063
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	KMT2B PHF20 SUV39H2 SETDB1 NFKB1 NFKB2 KDM4B	3.50e-04	175	106	7	MM14941
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ERBB3 VWF SUPT20H ANK3 MYO1E SMC1A LRSAM1 GNPTAB TMEM59 XPC MSH3 HUNK ZNF302 APP UBASH3A SETDB1 NPRL2 FBN1 SACS NOMO2 MYH14 PALS2 DYNC1H1 MITD1 XPOT	8.57e-11	1285	142	25	35914814
Pubmed	Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration.	NOMO1 NOMO2 NOMO3	6.66e-08	3	142	3	36011023
Pubmed	Silencing of nodal modulator 1 inhibits the differentiation of P19 cells into cardiomyocytes.	NOMO1 NOMO2 NOMO3	6.66e-08	3	142	3	25576386
Pubmed	Functional proteomics mapping of a human signaling pathway.	PAPPA2 FLNA MYH10 VWF KMT2B ANK3 RNPC3 XPC DDB1 NOMO1 SETDB1 SUSD1 DYNC1H1 NOMO3	1.57e-07	591	142	14	15231748
Pubmed	Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology.	NOMO1 NOMO2 NOMO3	2.66e-07	4	142	3	31833031
Pubmed	A locus for autosomal recessive pseudoxanthoma elasticum, with penetrance of vascular symptoms in carriers, maps to chromosome 16p13.1.	NOMO1 NOMO2 NOMO3	2.66e-07	4	142	3	9267806
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	ENPP6 FLNA MYH10 DNAJC13 VWF ANK3 MYO1E MAP2 FARSB BCL11A DDB1 SACS MYH14 PRKAA1 SCAPER PRICKLE2 PRKCG CPNE4 CORO7 DYNC1H1 DMTN	3.86e-07	1431	142	21	37142655
Pubmed	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.	UGT1A8 UGT1A7 UGT1A9	6.62e-07	5	142	3	20565459
Pubmed	A new role for the architecture of microvillar actin bundles in apical retention of membrane proteins.	FLNA MYH10 MYO1E MYO7B MYH14	1.13e-06	45	142	5	22114352
Pubmed	Protein-protein interactions between large proteins: two-hybrid screening using a functionally classified library composed of long cDNAs.	SH3RF1 CEMIP SETDB1 SCAPER CEP152 MED23 WDTC1	1.13e-06	130	142	7	12421765
Pubmed	Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability.	FLNA MYH10 MYO1E DDB1 NOMO1 MYH14 DYNC1H1 NOMO3	1.28e-06	191	142	8	33762435
Pubmed	Circadian Clock Component Rev-erbα Regulates Diurnal Rhythm of UDP-Glucuronosyltransferase 1a9 and Drug Glucuronidation in Mice.	UGT1A8 UGT1A7 UGT1A9	1.32e-06	6	142	3	32527940
Pubmed	Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes.	UGT1A8 UGT1A7 UGT1A9	1.32e-06	6	142	3	20297805
Pubmed	Network organization of the human autophagy system.	FLNA SMC1A VPS33A FARSB DDB1 RIF1 TRAPPC12 AGL PRKAA1 XPOT WDTC1	1.98e-06	437	142	11	20562859
Pubmed	Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37.	UGT1A8 UGT1A7 UGT1A9	2.30e-06	7	142	3	8467709
Pubmed	Filamin A-interacting protein (FILIP) is a region-specific modulator of myosin 2b and controls spine morphology and NMDA receptor accumulation.	FLNA MYH10 MAP2	2.30e-06	7	142	3	25220605
Pubmed	Cyp3a11-mediated testosterone-6β-hydroxylation decreased, while UGT1a9-mediated propofol O-glucuronidation increased, in mice with diabetes mellitus.	UGT1A8 UGT1A7 UGT1A9	2.30e-06	7	142	3	27514509
Pubmed	Molecular cloning of two cDNAs encoding the mouse bilirubin/phenol family of UDP-glucuronosyltransferases (mUGTBr/p).	UGT1A8 UGT1A7 UGT1A9	2.30e-06	7	142	3	8464825
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	PAPPA2 FLNA PRAMEF5 SUPT20H WDR81 FARSB TM6SF1 SLC7A2 PRAMEF6 XPOT	2.66e-06	363	142	10	14691545
Pubmed	Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.	UGT1A8 UGT1A7 UGT1A9	3.68e-06	8	142	3	20610558
Pubmed	Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms.	UGT1A8 UGT1A7 UGT1A9	3.68e-06	8	142	3	18052087
Pubmed	Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation.	UGT1A8 UGT1A7 UGT1A9	3.68e-06	8	142	3	17179145
Pubmed	Nicalin and its binding partner Nomo are novel Nodal signaling antagonists.	NOMO1 NOMO2 NOMO3	3.68e-06	8	142	3	15257293
Pubmed	A genome-wide association study identifies UGT1A1 as a regulator of serum cell-free DNA in young adults: The Cardiovascular Risk in Young Finns Study.	UGT1A8 UGT1A7 UGT1A9	5.50e-06	9	142	3	22511988
Pubmed	Substrate-driven assembly of a translocon for multipass membrane proteins.	NOMO1 NOMO2 NOMO3	5.50e-06	9	142	3	36261522
Pubmed	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.	FLNA MYH10 ANK3 SPOCK1 VPS33A WDR81 MUC5B DDB1 MYH14 PALS2 PGM2 HYDIN DYNC1H1 XPOT	6.08e-06	807	142	14	30575818
Pubmed	Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study.	UGT1A8 UGT1A7 UGT1A9	7.83e-06	10	142	3	23642732
Pubmed	UDP-glucuronosyltransferases.	UGT1A8 UGT1A7 UGT1A9	7.83e-06	10	142	3	11465080
Pubmed	A genome-wide association study for serum bilirubin levels and gene-environment interaction in a Chinese population.	UGT1A8 UGT1A7 UGT1A9	7.83e-06	10	142	3	23371916
Pubmed	A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia.	UGT1A8 UGT1A7 UGT1A9	7.83e-06	10	142	3	22558097
Pubmed	An ER translocon for multi-pass membrane protein biogenesis.	NOMO1 NOMO2 NOMO3	1.07e-05	11	142	3	32820719
Pubmed	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.	UGT1A8 UGT1A7 UGT1A9	1.07e-05	11	142	3	18695635
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	FLNA MYH10 DNAJC13 SMC1A ACP1 LRSAM1 FARSB XPC MSH3 COLGALT1 DDB1 RIF1 MYH14 NFKB2 A2ML1 CORO7 DYNC1H1 XPOT	1.08e-05	1353	142	18	29467282
Pubmed	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.	UGT1A8 UGT1A7 UGT1A9	1.43e-05	12	142	3	20308471
Pubmed	Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.	UGT1A8 UGT1A7 UGT1A9	1.43e-05	12	142	3	19419973
Pubmed	Mouse prickle1, the homolog of a PCP gene, is essential for epiblast apical-basal polarity.	PRICKLE1 PRICKLE2 PRKCG	1.43e-05	12	142	3	19706528
Pubmed	Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus.	UGT1A8 UGT1A7 UGT1A9	1.43e-05	12	142	3	11434514
Pubmed	Quantitative dissection and modeling of the NF-κB p100-p105 module reveals interdependent precursor proteolysis.	NFKB1 NFKB2	1.66e-05	2	142	2	25482563
Pubmed	FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.	ERBB3 FGFR2	1.66e-05	2	142	2	18381441
Pubmed	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	NFKB1 NFKB2	1.66e-05	2	142	2	28368397
Pubmed	NF-kappaB to the rescue: RELs, apoptosis and cellular transformation.	NFKB1 NFKB2	1.66e-05	2	142	2	10354583
Pubmed	Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene.	UGT1A7 UGT1A9	1.66e-05	2	142	2	11677206
Pubmed	Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.	UGT1A7 UGT1A9	1.66e-05	2	142	2	12944498
Pubmed	Induction of endothelial cell proliferation and von Willebrand factor expression and secretion by leukemic plasma of patients with chronic lymphocytic leukemia before and after inhibition of NF-κB.	VWF NFKB1	1.66e-05	2	142	2	27472040
Pubmed	Identification and characterization of human PRICKLE1 and PRICKLE2 genes as well as mouse Prickle1 and Prickle2 genes homologous to Drosophila tissue polarity gene prickle.	PRICKLE1 PRICKLE2	1.66e-05	2	142	2	12525887
Pubmed	Mutations in prickle orthologs cause seizures in flies, mice, and humans.	PRICKLE1 PRICKLE2	1.66e-05	2	142	2	21276947
Pubmed	Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells.	PRKAA1 SCNN1A	1.66e-05	2	142	2	15753079
Pubmed	Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.	UGT1A7 UGT1A9	1.66e-05	2	142	2	17529886
Pubmed	Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2.	NFKB1 NFKB2	1.66e-05	2	142	2	1612589
Pubmed	Dissociation of a BRICHOS trimer into monomers leads to increased inhibitory effect on Aβ42 fibril formation.	SFTPC APP	1.66e-05	2	142	2	25891900
Pubmed	Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.	NFKB1 NFKB2	1.66e-05	2	142	2	21846842
Pubmed	Analysis of NudCD1 and NF-κΒ in the early detection and course evaluation of renal cancer.	NFKB1 NUDCD1	1.66e-05	2	142	2	33336728
Pubmed	The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.	ERBB3 NFKB1	1.66e-05	2	142	2	25876877
Pubmed	NF-kappa B binds to the immunoglobulin S gamma 3 region in vivo during class switch recombination.	NFKB1 NFKB2	1.66e-05	2	142	2	17109470
Pubmed	Requirement for NF-kappaB in osteoclast and B-cell development.	NFKB1 NFKB2	1.66e-05	2	142	2	9407039
Pubmed	Mouse Prickle1 and Prickle2 are expressed in postmitotic neurons and promote neurite outgrowth.	PRICKLE1 PRICKLE2	1.66e-05	2	142	2	17868671
Pubmed	Filamin A Expression Negatively Regulates Sphingosine-1-Phosphate-Induced NF-κB Activation in Melanoma Cells by Inhibition of Akt Signaling.	FLNA NFKB1	1.66e-05	2	142	2	26552704
Pubmed	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.	UGT1A8 UGT1A9	1.66e-05	2	142	2	18568343
Pubmed	Involvement of NF-κB signaling pathway in the regulation of PRKAA1-mediated tumorigenesis in gastric cancer.	NFKB1 PRKAA1	1.66e-05	2	142	2	31841039
Pubmed	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.	UGT1A7 UGT1A9	1.66e-05	2	142	2	15709193
Pubmed	Protein kinase C-dependent alpha-secretory processing of the amyloid precursor protein is mediated by phosphorylation of myosin II-B.	MYH10 APP	1.66e-05	2	142	2	19103644
Pubmed	NF-{kappa}B is transported into the nucleus by importin {alpha}3 and importin {alpha}4.	NFKB1 NFKB2	1.66e-05	2	142	2	15677444
Pubmed	The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein.	TMEM59 APP	1.66e-05	2	142	2	20427278
Pubmed	Deletion of Calponin 2 in Mouse Fibroblasts Increases Myosin II-Dependent Cell Traction Force.	MYH10 CNN2	1.66e-05	2	142	2	27733037
Pubmed	Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.	NFKB1 NFKB2	1.66e-05	2	142	2	12568403
Pubmed	Protein kinase Cgamma regulates myosin IIB phosphorylation, cellular localization, and filament assembly.	MYH10 PRKCG	1.66e-05	2	142	2	16394101
Pubmed	A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers.	SFTPC APP	1.66e-05	2	142	2	25686087
Pubmed	Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism.	NFKB1 NFKB2	1.66e-05	2	142	2	18250170
Pubmed	New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases.	NFKB1 NFKB2	1.66e-05	2	142	2	9895331
Pubmed	Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial-mesenchymal transition.	MYH10 MYH14	1.66e-05	2	142	2	22025714
Pubmed	Role of Prickle1 and Prickle2 in neurite outgrowth in murine neuroblastoma cells.	PRICKLE1 PRICKLE2	1.66e-05	2	142	2	22218901
Pubmed	How do nuclear factor kappa B (NF-κB)1 and NF-κB2 defects lead to the incidence of clinical and immunological manifestations of inborn errors of immunity?	NFKB1 NFKB2	1.66e-05	2	142	2	36706462
Pubmed	Embryonic expression pattern of amyloid protein precursor suggests a role in differentiation of specific subsets of neurons.	MAP2 APP	1.66e-05	2	142	2	8207383
Pubmed	Nuclear factor-kappaB activated by capacitative Ca2+ entry enhances muscarinic receptor-mediated soluble amyloid precursor protein (sAPPalpha) release in SH-SY5Y cells.	APP NFKB1	1.66e-05	2	142	2	16490783
Pubmed	The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.	NFKB1 NFKB2	1.66e-05	2	142	2	16751281
Pubmed	Downregulation of myosin II-B by siRNA alters the subcellular localization of the amyloid precursor protein and increases amyloid-beta deposition in N2a cells.	MYH10 APP	1.66e-05	2	142	2	17727819
Pubmed	Prickle promotes the formation and maintenance of glutamatergic synapses by stabilizing the intercellular planar cell polarity complex.	PRICKLE1 PRICKLE2	1.66e-05	2	142	2	34613779
Pubmed	Lipopolysaccharides reduce adipogenesis in 3T3-L1 adipocytes through activation of NF-κB pathway and downregulation of AMPK expression.	NFKB1 PRKAA1	1.66e-05	2	142	2	23686584
Pubmed	Dcf1 alleviates C99-mediated deficits in drosophila by reducing the cleavage of C99.	TMEM59 APP	1.66e-05	2	142	2	32540098
Pubmed	Laminin stimulates and guides axonal outgrowth via growth cone myosin II activity.	MYH10 MYH14	1.66e-05	2	142	2	15880105
Pubmed	Analysis of NFKB1 and NFKB2 gene expression in the blood of patients with sudden sensorineural hearing loss.	NFKB1 NFKB2	1.66e-05	2	142	2	36773447
Pubmed	AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.	APP PRKAA1	1.66e-05	2	142	2	20080969
Pubmed	Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis.	MYH10 MYH14	1.66e-05	2	142	2	20861308
Pubmed	Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.	NFKB1 NFKB2	1.66e-05	2	142	2	9359707
Pubmed	Interactome of the Autoimmune Risk Protein ANKRD55.	FLNA MYH10 SMC1A FARSB DDB1 DYNC1H1 XPOT	1.75e-05	197	142	7	31620119
Pubmed	UGT1A1 is a major locus influencing bilirubin levels in African Americans.	UGT1A8 UGT1A7 UGT1A9	1.85e-05	13	142	3	22085899
Pubmed	Genome-wide analysis of hepatic lipid content in extreme obesity.	UGT1A8 UGT1A7 UGT1A9	1.85e-05	13	142	3	25246029
Pubmed	Docking motif-guided mapping of the interactome of protein phosphatase-1.	WDR81 SH2D4A SACS CSMD1 HYDIN	1.99e-05	80	142	5	19389623
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	FLNA MYH10 VWF RBM45 LRSAM1 BCL11A APP DDB1 NOMO1 FBN1 IPO13	2.04e-05	560	142	11	21653829
Pubmed	Fibrillin-2 is a key mediator of smooth muscle extracellular matrix homeostasis during mouse tracheal tubulogenesis.	SFTPC FBN1 NFKB1 NFKB2	2.17e-05	40	142	4	30578393
Pubmed	Human transcription factor protein interaction networks.	MYH10 SUPT20H KMT2B SMC1A COP1 BCL11A DDB1 LIN9 BAP1 SETDB1 RIF1 FBN1 MYH14 NFKB1 NFKB2 CEP152 DYNC1H1 XPOT	2.24e-05	1429	142	18	35140242
Pubmed	Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels.	UGT1A8 UGT1A7 UGT1A9	2.35e-05	14	142	3	21646302
Pubmed	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	UGT1A8 UGT1A7 UGT1A9	2.35e-05	14	142	3	10836148
Pubmed	Identification and overlapping expression of multiple unconventional myosin genes in vertebrate cell types.	MYO1E MYO7B MYH14	2.35e-05	14	142	3	8022818
Pubmed	The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.	UGT1A8 UGT1A7 UGT1A9	2.35e-05	14	142	3	9295054
Pubmed	Multiple variable first exons: a mechanism for cell- and tissue-specific gene regulation.	UGT1A8 UGT1A7 UGT1A9	2.35e-05	14	142	3	14672974
Pubmed	Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes.	NFKB1 NFKB2 PRKCG	2.92e-05	15	142	3	8627654
Pubmed	A human MAP kinase interactome.	FLNA MYH10 VWF SUPT20H SH3RF1 ANK3 LAMA3 SETDB1 RIF1 SH2D4A	3.33e-05	486	142	10	20936779
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	GALNT3 SPOCK1 ACP1 GNPTAB TMEM59 DCBLD1 COLGALT1 APP DDB1 CLCC1 NOMO1 IGSF10 FBN1 NOMO2 SCAPER IPO13	3.40e-05	1201	142	16	35696571
Pubmed	Biochemical Reduction of the Topology of the Diverse WDR76 Protein Interactome.	FLNA MYH10 SMC1A XPC MSH3 DDB1 FBN1	3.45e-05	219	142	7	31353912
Cytoband	2q37	UGT1A8 UGT1A7 UGT1A9	1.22e-04	31	142	3	2q37
GeneFamily	Prickle planar cell polarity proteins\|LIM domain containing	PRICKLE1 PRICKLE2	1.88e-04	4	102	2	1184
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	PAPPA2 CFHR4 SUSD1 CSMD1	3.00e-04	57	102	4	1179
GeneFamily	Ankyrin repeat domain containing\|NF-kappa B complex subunits	NFKB1 NFKB2	3.12e-04	5	102	2	1254
GeneFamily	UDP glucuronosyltransferases	UGT1A8 UGT1A7 UGT1A9	7.68e-04	32	102	3	363
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	KMT2B SUV39H2 SETDB1	9.19e-04	34	102	3	487
GeneFamily	Copines	CPNE4 CPNE7	1.11e-03	9	102	2	829
GeneFamily	Tudor domain containing	PHF20 SETDB1 KDM4B	1.18e-03	37	102	3	780
GeneFamily	Doublecortin superfamily	DCDC2C DCDC1	1.38e-03	10	102	2	1369
GeneFamily	Myosin heavy chains	MYH10 MYH14	3.15e-03	15	102	2	1098
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	WDR81 SH2D4A SACS CSMD1 HYDIN	3.62e-03	181	102	5	694
GeneFamily	Sulfatases	ARSJ ARSI	4.55e-03	18	102	2	410
ToppCell	PND01-03-samps-Epithelial-Alveolar_epithelial\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	ERBB3 ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2 PGM2	1.60e-07	187	142	8	23fe3cdd6cc9b067086a8392d104186d300298ea
ToppCell	human_hepatoblastoma-Tumor_cells-T5\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	SH3RF1 ANK3 MYO1E HUNK PRICKLE2 ADAMTS18 FGFR2 HYDIN	1.67e-07	188	142	8	b070a0667f1ee9b825b267b6c389b7c42fc436f9
ToppCell	ASK454-Endothelial-Lymphatic\|Endothelial / Donor, Lineage and Cell class of Lung cells from Dropseq	MYH10 DNAJC13 SPAG8 UBASH3A FBN1 MYH14 SCNN1A CPNE7	1.73e-07	189	142	8	316c857dec9383823e09f966bca62d52d933b141
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Artery\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	VWF MYO1E TM6SF1 TIAM2 FBN1 HMCN1 CSMD1 PCDH10	1.73e-07	189	142	8	c45734970036e6d28d5e3fe7c9458fae38a3f624
ToppCell	COPD-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	VWF MYO1E NOMO1 SLC7A2 RND1 NOMO2 CSMD1 NOMO3	1.88e-07	191	142	8	ef16ad1c1cd2c0c0377957398c98775b62a81754
ToppCell	COPD-Epithelial\|COPD / Disease state, Lineage and Cell class	SH3RF1 ANK3 SLC7A2 MYH14 SCNN1A PRICKLE2 FGFR2 HYDIN	1.96e-07	192	142	8	0644fad5df18f0021f6f49cca996d8cf47f972ff
ToppCell	Control-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	VWF MYO1E NOMO1 SLC7A2 RND1 NOMO2 CSMD1 NOMO3	1.96e-07	192	142	8	7e89b9125e8b85f6be85eeccef5c8644647ab0e1
ToppCell	LPS_IL1RA_TNF\|World / Treatment groups by lineage, cell group, cell type	ENPP6 MYH10 SFTPC LAMA3 ARSI IGSF10 PXDNL SCNN1A	2.38e-07	197	142	8	0a6550dce156fc81f15b1e7830d331ca50d87d06
ToppCell	Sepsis-Leuk-UTI-Myeloid-tDC\|Leuk-UTI / Disease, condition lineage and cell class	GALNT3 DUSP5 APP TM6SF1 TTK IGSF10 SUSD1 NOMO2	2.57e-07	199	142	8	a2f154b15087803958a656d2a41b6d83fd37b32f
ToppCell	Leuk-UTI-Myeloid-tDC\|Leuk-UTI / Disease, Lineage and Cell Type	GALNT3 DUSP5 APP TTK IGSF10 SUSD1 NOMO2	8.74e-07	161	142	7	51b9f60986ed2e8e2297d31c80462c3ab65a2e5e
ToppCell	facs-Lung-nan-3m-Epithelial-type_I_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 MAP2 LAMA3 SPAG8 SH2D4A SCNN1A FGFR2	1.07e-06	166	142	7	11b0ae82b3068ef91715dbdd49fe8e9791b4a480
ToppCell	facs-Lung-nan-3m-Epithelial-Alveolar_Epithelial_Type_1\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 MAP2 LAMA3 SPAG8 SH2D4A SCNN1A FGFR2	1.07e-06	166	142	7	fcc1aec31ebd39432d4cb284dc8fadf34e3c566a
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ERBB3 ANK3 SFTPC LAMA3 SH2D4A MYH14 SCNN1A	1.41e-06	173	142	7	45808cf69122c16b9d2b5ffa06d15392c55954b7
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2-AT1/AT2_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ERBB3 ANK3 SFTPC LAMA3 SH2D4A MYH14 SCNN1A	1.41e-06	173	142	7	7fa9dbcb258c3ab974490063951620e2def03db1
ToppCell	LPS-IL1RA+antiTNF\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 SFTPC LAMA3 IGSF10 MYH14 PXDNL SCNN1A	1.65e-06	177	142	7	b7fee75de7e96924af488a5baa2334711889ae7c
ToppCell	LPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARSJ ANK3 SFTPC LAMA3 SH2D4A MYH14 FGFR2	1.77e-06	179	142	7	fd2cbee532e7b44113410dca82aec7db1a7fb69f
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 ARSJ SH3RF1 ARSI IGSF10 SLC7A2 PXDNL	1.84e-06	180	142	7	08ae0f5d95c45feba68ad99788f7af7ff4c979af
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 ARSJ SH3RF1 ARSI IGSF10 SLC7A2 PXDNL	1.84e-06	180	142	7	9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 ARSJ SH3RF1 ARSI IGSF10 SLC7A2 PXDNL	1.91e-06	181	142	7	9e7d0f1afb8d9bc5a209ddb5314df3a25a0274d9
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO7B MUC5B HMCN1 PTPRQ CSMD1 PCDH10 HYDIN	2.13e-06	184	142	7	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO7B MUC5B HMCN1 PTPRQ CSMD1 PCDH10 HYDIN	2.13e-06	184	142	7	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO7B MUC5B HMCN1 PTPRQ CSMD1 PCDH10 HYDIN	2.13e-06	184	142	7	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	GNPTAB LIN9 HMCN1 ZNF45 AGL PRKAA1 ANKRD12	2.29e-06	186	142	7	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1\|Adult / Lineage, Cell type, age group and donor	ARSJ SH3RF1 MAP2 LAMA3 MYH14 PTPRQ SCNN1A	2.37e-06	187	142	7	77f78aec946bc6bd85c29aee9ca978ce49f853a3
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Outer_Medullary_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 ARSJ ANK3 MYO1E HUNK SUSD1 CNGA1	2.37e-06	187	142	7	e3095455d2f255854f339f6b05fa87852af0700f
ToppCell	COVID-19-Epithelial_cells\|COVID-19 / group, cell type (main and fine annotations)	ERBB3 ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	2.46e-06	188	142	7	c9cdee6f8d42ee69f5fb335f25084603c511bd29
ToppCell	Control-Epithelial_cells\|Control / group, cell type (main and fine annotations)	SH3RF1 ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	2.46e-06	188	142	7	707ebf76cc6fb600b2f07793cf4ea9482c0de79d
ToppCell	IPF-Epithelial-Club\|IPF / Disease state, Lineage and Cell class	ERBB3 SH3RF1 ANK3 UGT1A8 MYH14 SCNN1A FGFR2	2.55e-06	189	142	7	f3fcef008ef252b29ac6d567fef27f9acf9cd70f
ToppCell	E18.5-samps-Epithelial\|E18.5-samps / Age Group, Lineage, Cell class and subclass	ERBB3 ANK3 SFTPC LAMA3 MYH14 FGFR2 PGM2	2.64e-06	190	142	7	90accc078e9a72329a415d5cefe062c4196bb624
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	2.73e-06	191	142	7	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	E18.5-samps-Epithelial-Alveolar_epithelial\|E18.5-samps / Age Group, Lineage, Cell class and subclass	ERBB3 ANK3 SFTPC LAMA3 MYH14 FGFR2 PGM2	2.73e-06	191	142	7	1cd4d513ac363fdda07030b85a88174d29af3588
ToppCell	IPF-Epithelial-Club\|World / Disease state, Lineage and Cell class	ERBB3 SH3RF1 ANK3 UGT1A8 MYH14 SCNN1A FGFR2	2.73e-06	191	142	7	3c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954
ToppCell	IPF-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	SH3RF1 MAP2 NOMO1 SLC7A2 HMCN1 NOMO2 NOMO3	2.82e-06	192	142	7	e911e286da26202853f9650ba3cdefe5a5c9b585
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	2.82e-06	192	142	7	f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	2.82e-06	192	142	7	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	PND03-Epithelial\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 SCNN1A FGFR2	2.82e-06	192	142	7	d8c23693f690d4d568585537bbfedda05d505b3d
ToppCell	facs-Lung-nan-3m-Epithelial\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 ANK3 SFTPC SH2D4A MYH14 SCNN1A FGFR2	2.82e-06	192	142	7	cca2d0fedfbd946c54d6f4fc45887117c8dae58a
ToppCell	Epithelial\|World / shred on cell class and cell subclass (v4)	ANK3 SFTPC APP SH2D4A MYH14 SCNN1A FGFR2	2.82e-06	192	142	7	13a3553d9a7c78535679d23d454c63fd08f7d218
ToppCell	E18.5-Epithelial\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 FGFR2 PGM2	2.82e-06	192	142	7	75bc06ce38478f06ba29a2cc3d238aa26e87a951
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	2.82e-06	192	142	7	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	PND03-Epithelial-Epithelial_Alveolar\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 SCNN1A FGFR2	2.92e-06	193	142	7	5dfa69a680a0859900141c40a446d217aaa747d3
ToppCell	PND03-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 SCNN1A FGFR2	2.92e-06	193	142	7	ebea35704ac5d21e947ae094313cf2a5205e7014
ToppCell	E18.5-Epithelial-Epithelial_Alveolar\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 FGFR2 PGM2	2.92e-06	193	142	7	8e750a2b198ad6840a6842a7ddd93623faf7c656
ToppCell	E18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 SFTPC APP SH2D4A MYH14 FGFR2 PGM2	2.92e-06	193	142	7	6cc09f20dd119236c3c9968f3d16c3eabc0811e2
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	2.92e-06	193	142	7	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	nucseq-Epithelial-Epithelial_Alveolar\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SH3RF1 ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	3.02e-06	194	142	7	53f3e49e91b1096f3226010e2de767efb490dfe4
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 SLC7A2 FBN1 PXDNL	3.02e-06	194	142	7	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	nucseq-Epithelial\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SH3RF1 ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	3.13e-06	195	142	7	9406866f99555198a9be311fbd65751b70f35446
ToppCell	Control-Epithelial\|Control / Disease state, Lineage and Cell class	ERBB3 SH3RF1 ANK3 SLC7A2 MYH14 SCNN1A FGFR2	3.13e-06	195	142	7	1798c3b89b1b5ff4f5777d2b9f52dc81cdad28fa
ToppCell	IPF-Epithelial\|IPF / Disease state, Lineage and Cell class	DCDC1 ANK3 NEK5 MYH14 SCNN1A PRICKLE2 HYDIN	3.24e-06	196	142	7	87d9881cfec461a5d89b688a83749b618c519485
ToppCell	Control_saline-Epithelial_alveolar-AT_2-Differentiating_AT2\|Control_saline / Treatment groups by lineage, cell group, cell type	GALNT3 ANK3 SFTPC RNPC3 LAMA3 MYH14 FGFR2	3.35e-06	197	142	7	44a59dfb889577b3160a5b13ada1276771a00241
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ARSJ GALNT3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	3.70e-06	200	142	7	c89f3cb36bb14c476d6a392bfd3ded1c8feecfeb
ToppCell	control\|World / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ERBB3 ANK3 MFSD6 APP SLC7A2 MYH14 SCNN1A	3.70e-06	200	142	7	97f36d2c197e03d93a1fc59949d77ae90f6e6a9a
ToppCell	Lung_Parenchyma-Control-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	ERBB3 GALNT3 ANK3 SFTPC MYH14 SCNN1A FGFR2	3.70e-06	200	142	7	c2bde99b3bc7a8740441c1a0c1394892b940b857
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	ERBB3 GALNT3 ANK3 SFTPC MYH14 SCNN1A FGFR2	3.70e-06	200	142	7	3ff9abd5e07780a59d5571da906fa15f00a1d5c2
ToppCell	Control_saline-Endothelial-Endothelial-Artery\|Control_saline / Treatment groups by lineage, cell group, cell type	VWF ARSJ TM6SF1 TIAM2 FBN1 HMCN1 PCDH10	3.70e-06	200	142	7	65b71f1e8da5c3750fcd0a2e66d9ef3125a3f78a
ToppCell	NS-control\|NS / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ERBB3 ANK3 MFSD6 APP SLC7A2 MYH14 SCNN1A	3.70e-06	200	142	7	ecbe89ff95d046155b984c8c150e0b9e7278f839
ToppCell	Parenchyma_Control_(B.)-Epithelial-TX\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	ERBB3 GALNT3 ANK3 SFTPC MYH14 SCNN1A FGFR2	3.70e-06	200	142	7	9970e9bde6aa2ff3aef60dcb065ff15b7463e147
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Pvalb-Pvalb_Sema3e_Kank4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYO1E LAMA3 UROC1 TM6SF1 CEMIP MYH14	4.78e-06	135	142	6	54b2aaf8d322e01a3ff6099c2422d68ecccf96b4
ToppCell	P15-Epithelial-epithelial_progenitor_cell-epithelial_progenitor_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ERBB3 ANK3 SFTPC MUC5B MYH14 SCNN1A	7.80e-06	147	142	6	aba44c7057096483c4293a7ebcf8ccc8baed0231
ToppCell	P15-Epithelial-epithelial_progenitor_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ERBB3 ANK3 SFTPC MUC5B MYH14 SCNN1A	9.44e-06	152	142	6	00d5503d462cfa009fb4cac79ecee11725a18b9a
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Pvalb-Pvalb_Gpr149_Islr\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYO1E LAMA3 HUNK TM6SF1 CEMIP MYH14	1.22e-05	159	142	6	c64fff8d89f84d1f5a0cc432e31f56f741162505
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	SFTPC DUSP5 TIAM2 PRKCG TMPRSS7 HYDIN	1.31e-05	161	142	6	ba7ce599b173cf81c8323e7c96dc3d57379f1ed6
ToppCell	facs-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ERBB3 MAP2 LAMA3 SH2D4A MYH14 SCNN1A	1.61e-05	167	142	6	bebc2493a2ee41920b21c2b774a1c5a9619315c4
ToppCell	facs-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte-type_1_alveolar_epithelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ERBB3 MAP2 LAMA3 SH2D4A MYH14 SCNN1A	1.61e-05	167	142	6	9f2661729a2d58e17a9203a563d538c08a3dbbbc
ToppCell	Control\|World / group, cell type (main and fine annotations)	SH3RF1 ANK3 SFTPC LAMA3 SLC7A2 MYH14	1.67e-05	168	142	6	a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCell	P28-Epithelial-epithelial_progenitor_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ERBB3 DCDC2C ANK3 SFTPC MYH14 SCNN1A	1.67e-05	168	142	6	03c95ad3684caec7a6d581006b237cc5fa230685
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB3 SH3RF1 ANK3 MYH14 SCNN1A PRICKLE2	1.78e-05	170	142	6	a2c738e441ced90eeeb1fcc6ca3269b918aaa298
ToppCell	P28-Epithelial-epithelial_progenitor_cell-epithelial_progenitor_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ERBB3 DCDC2C ANK3 SFTPC MYH14 SCNN1A	1.78e-05	170	142	6	d0ed3a8a7ad96c05641ec409b0a69c4fb094893c
ToppCell	P07-Epithelial\|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ANK3 SFTPC SH2D4A MYH14 SCNN1A FGFR2	1.97e-05	173	142	6	8b10087a917b825809d35a2b2b349c73a2782472
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ERBB3 ANK3 DUSP5 MUC5B MYH14 SCNN1A	2.38e-05	179	142	6	6e965e424eebef50f0202cff75f458be395cfca1
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB3 SH3RF1 ANK3 LAMA3 SCNN1A FGFR2	2.38e-05	179	142	6	cb38b54261a7af5ee3347e64c8aa880a77ed0763
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5-Exc_L4-5_RORB_HNRNPA1P46\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARSJ BCL11A CRHR2 CPNE4 PCDH10 CPNE7	2.38e-05	179	142	6	53e700494d251ec5649b2dea5fc7d5aeeeed572b
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARSJ ANK3 SFTPC IDI1 MYH14 FGFR2	2.38e-05	179	142	6	7db6b97a1c4c7a163d5da4351ba36ac1785d9d7b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 ANK3 MYO1E HUNK SUSD1 CNGA1	2.46e-05	180	142	6	023ec0b080c8a5cd0f36e83c6b17d4be3c01edb5
ToppCell	P03-Epithelial\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ANK3 SFTPC SH2D4A MYH14 SCNN1A FGFR2	2.54e-05	181	142	6	de0466072f5b2ab8db3d9bab31e3205d1ff7cfb7
ToppCell	COPD-Epithelial-Basal\|World / Disease state, Lineage and Cell class	ARSJ SH3RF1 ANK3 UGT1A8 PTPRQ FGFR2	2.54e-05	181	142	6	6d8a886b4afe729f8a05b9c0f4ea9375de735da4
ToppCell	COVID-19-Epithelial_cells-ECM-high_epithelial\|COVID-19 / group, cell type (main and fine annotations)	ANK3 MAP2 SFTPC LAMA3 MYH14 SCNN1A	2.70e-05	183	142	6	dc1d380bf7564f290256cb7108063d1bd2da732b
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	LAMA3 SH2D4A MYH14 PTPRQ SCNN1A FGFR2	2.70e-05	183	142	6	ff6dde877659cde9daa3263db0932c9c9ef1adac
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SH3RF1 MAP2 LAMA3 MYH14 PTPRQ SCNN1A	2.78e-05	184	142	6	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SH3RF1 MAP2 LAMA3 MYH14 PTPRQ SCNN1A	2.78e-05	184	142	6	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ARSJ SH3RF1 MAP2 LAMA3 MYH14 PTPRQ	2.87e-05	185	142	6	1c222f7285d6e3dae0354dc7e853ddc0ea55e63e
ToppCell	Control-Epithelial_alveolar-AT_2-Differentiating_AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARSJ ANK3 SFTPC LAMA3 MYH14 FGFR2	2.87e-05	185	142	6	0d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D175\|Adult / Lineage, Cell type, age group and donor	ARSJ SH3RF1 MAP2 LAMA3 MYH14 PTPRQ	2.87e-05	185	142	6	32b4e68e551d435a732f253f6ad83408c759a642
ToppCell	PND01-03-samps-Epithelial\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	ANK3 SFTPC LAMA3 MYH14 SCNN1A FGFR2	2.87e-05	185	142	6	2b854df79cfe2cb4d2f9c2938a066e0aa3649325
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARSJ ANK3 SFTPC LAMA3 MYH14 FGFR2	2.87e-05	185	142	6	929b68b05b7686341329ac756d7df172cb4b810b
ToppCell	Control-Endothelial-Endothelial-Artery\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	VWF ARSJ TM6SF1 TIAM2 HMCN1 PCDH10	2.96e-05	186	142	6	2d3a975d2bf92e18e3410dd413fc9f84831d82de
ToppCell	Control-Epithelial-Club\|World / Disease state, Lineage and Cell class	ERBB3 SH3RF1 ANK3 MYH14 SCNN1A FGFR2	2.96e-05	186	142	6	9798428691408e17ff2af2fe2d1b345f074d67e4
ToppCell	facs-Lung-EPCAM-3m\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANK3 SFTPC MYH14 ACOT2 FGFR2 CNN2	2.96e-05	186	142	6	7c4eb769574f9f32753cea1cc38c711dabba88b9
ToppCell	Epithelial-alveolar_epithelial_cell_type_1\|World / Lineage, Cell type, age group and donor	ARSJ SH3RF1 MAP2 LAMA3 MYH14 PTPRQ	2.96e-05	186	142	6	09d95daa3387a4814cffaa4b798cc2810c3759d0
ToppCell	E17.5-Epithelial\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ANK3 SFTPC APP SH2D4A MYH14 FGFR2	3.05e-05	187	142	6	fdabe716ce67f2eede90548198cbe20bbf693570
ToppCell	367C-Epithelial_cells-Epithelial-E_(AT2)-\|367C / Donor, Lineage, Cell class and subclass (all cells)	ERBB3 ANK3 SFTPC MYH14 SCNN1A FGFR2	3.05e-05	187	142	6	11670a85db87cbb3e78022a589632173604b0940
ToppCell	367C-Epithelial_cells-Epithelial-E_(AT2)\|367C / Donor, Lineage, Cell class and subclass (all cells)	ERBB3 ANK3 SFTPC MYH14 SCNN1A FGFR2	3.05e-05	187	142	6	0277d4e54bd4d48f30241c2951a569209423fee8
ToppCell	COVID-19-kidney-CD-IC-B\|kidney / Disease (COVID-19 only), tissue and cell type	ARSJ SH2D4A SUSD1 SACS SCNN1A ADAMTS18	3.05e-05	187	142	6	ce05b89860573fe0356102e2998d1ef6d1968034
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 ANK3 MYO1E HUNK SUSD1 CNGA1	3.14e-05	188	142	6	e30a4ddac0da8cdcf621d98e28e3895cd9307e7a
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 FBN1 PXDNL	3.23e-05	189	142	6	a153b83314cf52808f685296cff8c95af3f4983d
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP6 MYH10 ARSI IGSF10 FBN1 PXDNL	3.23e-05	189	142	6	e9d5e858e320c6e9913c1ea6a54967d21eda605f
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PAPPA2 SH3RF1 MYO1E MYH14 PRICKLE2 HYDIN	3.23e-05	189	142	6	aadb7a2de4cbe7f0958651f2739bba430b93f5c1
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 ANK3 MYO1E HUNK SUSD1 CNGA1	3.23e-05	189	142	6	fc88c51ace7d883c01617f3f9b5fab70cc91cc09
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PAPPA2 SH3RF1 MYO1E MYH14 PRICKLE2 HYDIN	3.23e-05	189	142	6	8977f3295b7df7c7474b3f371de90a82ae4bb50c
Drug	ASA404	UGT1A8 UGT1A7 UGT1A9 RIF1 NFKB1 NFKB2	8.79e-07	53	140	6	CID000123964
Drug	naringenin chalcone	UGT1A8 UGT1A7 UGT1A9	2.26e-06	5	140	3	ctd:C027329
Drug	anthrarobin	UGT1A8 UGT1A7 UGT1A9	2.26e-06	5	140	3	ctd:C032186
Drug	Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	ARSJ CEMIP RIF1 FBN1 SCAPER FGFR2 DMTN TBCEL WDTC1	3.58e-06	196	140	9	6824_UP
Drug	Sulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	MYO1E SFTPC SPAG8 TM6SF1 SLC7A2 MYH14 SCAPER TBCEL WDTC1	3.89e-06	198	140	9	3609_DN
Drug	1,2,5,8-tetrahydroxy anthraquinone	UGT1A8 UGT1A7 UGT1A9	4.49e-06	6	140	3	ctd:C543211
Drug	alloin	UGT1A8 UGT1A7 UGT1A9	4.49e-06	6	140	3	ctd:C006457
Drug	2',5'-dihydroxychalcone	UGT1A8 UGT1A7 UGT1A9	4.49e-06	6	140	3	ctd:C107497
Drug	2',4'-dihydroxychalcone	UGT1A8 UGT1A7 UGT1A9	7.82e-06	7	140	3	ctd:C059354
Drug	ciprofibrate	UGT1A8 UGT1A7 UGT1A9 CFHR4 NFKB1 NFKB2 LPAL2 MED23	1.06e-05	170	140	8	CID000002763
Drug	1,4-dihydroxyanthraquinone	UGT1A8 UGT1A7 UGT1A9	1.25e-05	8	140	3	ctd:C034890
Drug	4-nitrophenol	RNPC3 UGT1A8 UGT1A7 ACP1 UGT1A9 SACS ANKRD12 DMTN	1.42e-05	177	140	8	CID000000980
Drug	5-MOP	UGT1A8 UGT1A7 UGT1A9 AFM	1.57e-05	25	140	4	CID000002355
Drug	Hymecromone	UGT1A8 UGT1A7 UGT1A9 FBN1	1.57e-05	25	140	4	ctd:D006923
Drug	AC1MRQNQ	UGT1A8 UGT1A7 UGT1A9	1.86e-05	9	140	3	CID003522271
Drug	DHPASiU	UGT1A8 UGT1A7 UGT1A9	1.86e-05	9	140	3	CID000197602
Drug	3-iodophenol	UGT1A8 UGT1A7 UGT1A9	1.86e-05	9	140	3	CID000012272
Drug	AC1L4J7U	UGT1A8 UGT1A7 UGT1A9	1.86e-05	9	140	3	CID000186631
Drug	Chebi:32663	UGT1A8 UGT1A7 UGT1A9	1.86e-05	9	140	3	CID005460873
Drug	Dobutamine hydrochloride [49745-95-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	PAPPA2 MUC5B CRHR2 CEMIP ZNF276 MYH14 SCAPER DMTN	1.96e-05	185	140	8	6286_UP
Drug	indole-3-carbinol	MYH10 VWF MYO7B UGT1A8 GNPTAB LAMA3 APP CLCC1 SUSD1 SACS MYH14 NFKB1 A2ML1 SCNN1A ACOT2 FGFR2 PALS2 CSMD1 TMPRSS7 FER1L5	1.98e-05	1130	140	20	ctd:C016517
Drug	Scopoletin	UGT1A8 UGT1A7 UGT1A9 XPC	2.15e-05	27	140	4	ctd:D012603
Drug	2,6-dihydroxyanthraquinone	UGT1A8 UGT1A7 UGT1A9	2.65e-05	10	140	3	ctd:C034889
Drug	AC1N6UEL	AFM NFKB1 NFKB2	2.65e-05	10	140	3	CID004221373
Drug	Felodipine [72509-76-3]; Down 200; 10.4uM; PC3; HT_HG-U133A	PHF20 SMC1A BCL11A CEMIP RIF1 ZNF276 SCAPER FGFR2	2.75e-05	194	140	8	6695_DN
Drug	Sulfanilamide [63-74-1]; Down 200; 23.2uM; PC3; HT_HG-U133A	SUPT20H SMC1A MUC5B BCL11A TM6SF1 CEMIP SCAPER WDTC1	3.07e-05	197	140	8	4474_DN
Drug	S(-)-terguride hydrogen maleate [37686-85-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A	PAPPA2 SUPT20H GALNT3 CRHR2 SCAPER SCNN1A KDM4B TBCEL	3.18e-05	198	140	8	6473_UP
Drug	D.E.T	COP1 DDB1 SETDB1 DMTN	3.31e-05	30	140	4	CID000006090
Drug	4-nitrophenyl)imidazole	UGT1A8 UGT1A7 UGT1A9	3.62e-05	11	140	3	CID000123155
Drug	AC1O5XMV	UGT1A8 UGT1A7 UGT1A9	3.62e-05	11	140	3	CID006442661
Drug	Z 338	UGT1A8 UGT1A9	3.75e-05	2	140	2	ctd:C410959
Drug	N-OH-DABZ	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	CID000051366
Drug	1-O-beta-D-glucopyranosyl-D-mannitol	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	CID000088735
Drug	4-hydroxyestrone	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	ctd:C026418
Drug	2,4,6-TCB	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	CID000037247
Drug	nonanoyl-N-methylglucamide	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	CID000160090
Drug	7,7,7-triphenylheptanoic acid	UGT1A8 UGT1A7 UGT1A9	4.81e-05	12	140	3	CID000276709
Drug	geniposide	VWF UGT1A8 UGT1A7 UGT1A9	4.88e-05	33	140	4	CID000107848
Drug	2-hydroxyestrone	UGT1A8 UGT1A7 UGT1A9	6.22e-05	13	140	3	ctd:C024980
Drug	tritanol	UGT1A8 UGT1A7 UGT1A9	6.22e-05	13	140	3	CID000006457
Drug	5-azido-UDP-glucuronic acid	UGT1A8 UGT1A7 UGT1A9	6.22e-05	13	140	3	CID003081279
Drug	cotinine-N-glucuronide	UGT1A8 UGT1A7 UGT1A9	6.22e-05	13	140	3	CID000000411
Drug	alizarin	UGT1A8 UGT1A7 UGT1A9	6.22e-05	13	140	3	ctd:C010078
Drug	AC1L9DGV	FLNA UGT1A8 UGT1A7 UGT1A9	6.92e-05	36	140	4	CID000417381
Drug	anisole	UGT1A8 UGT1A7 UGT1A9 APP	6.92e-05	36	140	4	CID000007519
Drug	propranolol glucuronide	UGT1A8 UGT1A7 UGT1A9	7.88e-05	14	140	3	CID000119515
Drug	PCB-61	UGT1A8 UGT1A7 UGT1A9	7.88e-05	14	140	3	CID000036401
Drug	Ibuprofen	UGT1A8 UGT1A7 DUSP5 WDR81 LAMA3 UGT1A9 APP PANK1 LIN9 NFKB1 XPOT	8.48e-05	437	140	11	ctd:D007052
Drug	2,2',3,5,5'-pentachlorobiphenyl	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	CID000040469
Drug	afloqualone	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	CID000002040
Drug	naphthyl sulphate	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	CID000114775
Drug	coumarin-3-carboxylic acid	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	CID000010752
Drug	bergamottin	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	ctd:C068337
Drug	sulforaphane nitrile	UGT1A8 UGT1A7 UGT1A9	9.81e-05	15	140	3	CID000543743
Drug	harmol	UGT1A8 UGT1A7 UGT1A9 DMTN	1.05e-04	40	140	4	CID000068094
Drug	thymoquinone	UGT1A8 UGT1A7 UGT1A9 MITD1	1.05e-04	40	140	4	CID000010281
Drug	buprenorphine hydrochloride solution	UGT1A8 UGT1A7 UGT1A9 DMTN	1.16e-04	41	140	4	CID000002476
Drug	Ivermectin [70288-86-7]; Up 200; 4.6uM; MCF7; HT_HG-U133A	SFTPC CEMIP SLC7A2 RND1 MYH14 TREM1 KDM4B	1.19e-04	178	140	7	2213_UP
Drug	quercetin-3,4'-diglucoside	UGT1A8 UGT1A7 UGT1A9	1.20e-04	16	140	3	CID005320835
Drug	1'-hydroxyestragole	UGT1A8 UGT1A7 UGT1A9	1.20e-04	16	140	3	CID000040003
Drug	bilirubin-phosphate	UGT1A8 UGT1A7 UGT1A9	1.20e-04	16	140	3	CID005497144
Drug	3 beta,5 alpha,25R)- 3-hydroxyspirostan-12-one	UGT1A8 UGT1A7 UGT1A9	1.45e-04	17	140	3	CID000003573
Drug	6-hydroxychrysene	UGT1A8 UGT1A7 UGT1A9	1.45e-04	17	140	3	CID000037766
Drug	anthraflavic acid	UGT1A8 UGT1A7 UGT1A9 CFHR4	1.54e-04	44	140	4	CID000006776
Drug	SureCN12722713	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID005488034
Drug	ethyl-beta-D-6-glucosiduronic acid	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID000152226
Drug	Br 2	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID003060900
Drug	2,3,7-trichlorodibenzo-p-dioxin	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID000036614
Drug	ApApG	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID003081975
Drug	C1 11-32	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID000443077
Drug	C11131	UGT1A8 UGT1A7 UGT1A9	1.74e-04	18	140	3	CID000443076
Drug	Hycanthone [3105-97-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A	SMC1A SPAG8 APP CEMIP NFKB2 SCAPER WDTC1	1.96e-04	193	140	7	3229_DN
Drug	troglitazone; Down 200; 10uM; PC3; HG-U133A	KMT2B VPS33A MUC5B FZD8 FBN1 ANKRD12 KDM4B	1.96e-04	193	140	7	462_DN
Drug	9-OH-risperidone	UGT1A8 UGT1A7 UGT1A9	2.05e-04	19	140	3	CID000475100
Drug	5alpha-spirostan-3beta-ol	UGT1A8 UGT1A7 UGT1A9	2.05e-04	19	140	3	CID000091433
Drug	almokalant	UGT1A8 UGT1A7 UGT1A9	2.05e-04	19	140	3	CID003033962
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	SFTPC TM6SF1 SLC7A2 NFKB2 FGFR2 DMTN WDTC1	2.09e-04	195	140	7	3893_DN
Drug	Atropine-N-oxide hydrochloride [4574-60-1]; Up 200; 11.8uM; HL60; HG-U133A	MSH3 APP CLCC1 FASTK AGL CEP152 PALS2	2.09e-04	195	140	7	1370_UP
Drug	rosiglitazone; Down 200; 10uM; HL60; HT_HG-U133A	KMT2B VPS33A XPC MSH3 ZNF248 SCAPER WDTC1	2.15e-04	196	140	7	1174_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A	SUPT20H ANK3 MYO1E APP FGFR2 DYNC1H1 WDTC1	2.15e-04	196	140	7	1543_DN
Drug	Hydrocortisone base [50-23-7]; Down 200; 11uM; PC3; HT_HG-U133A	PHF20 SMC1A BCL11A TM6SF1 CLCC1 CEMIP SETDB1	2.15e-04	196	140	7	6684_DN
Drug	Nifedipine [21829-25-4]; Up 200; 11.6uM; HL60; HT_HG-U133A	PAPPA2 SUPT20H PHF20 SCAPER DMTN CPNE7 WDTC1	2.15e-04	196	140	7	1856_UP
Drug	Amphotericin B [1397-89-3]; Up 200; 4.4uM; HL60; HT_HG-U133A	PAPPA2 MYH10 MFSD6 RND1 NFKB1 NFKB2 WDTC1	2.15e-04	196	140	7	2441_UP
Drug	retigabine	ANK3 UGT1A8 UGT1A7 UGT1A9	2.16e-04	48	140	4	CID000121892
Drug	Norethindrone [68-22-4]; Down 200; 13.4uM; PC3; HT_HG-U133A	SMC1A VPS33A MFSD6 SPAG8 DMTN CPNE7 WDTC1	2.22e-04	197	140	7	5055_DN
Drug	N6,2-O-dibutyryladenosine 3,5-cyclic monophosphate sodium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA	COLGALT1 CEMIP RND1 FASTK NFKB2 CEP152 FGFR2	2.22e-04	197	140	7	959_UP
Drug	Harmine hydrochloride [343-27-1]; Up 200; 16uM; HL60; HG-U133A	KMT2B SFTPC BCL11A DCLRE1C TRAPPC12 MYH14 NFKB2	2.22e-04	197	140	7	1758_UP
Drug	Stachydrine hydrochloride; Up 200; 22.2uM; MCF7; HT_HG-U133A	PAPPA2 GALNT3 APP SLC7A2 RND1 ZNF45 MED23	2.22e-04	197	140	7	2743_UP
Drug	sitafloxacin	UGT1A7 UGT1A9	2.23e-04	4	140	2	ctd:C076246
Drug	hydratropic acid	UGT1A8 UGT1A7	2.23e-04	4	140	2	ctd:C013025
Drug	2-vanillin	UGT1A8 UGT1A7	2.23e-04	4	140	2	ctd:C060843
Drug	Thalidomide	NFKB1 FGFR2	2.23e-04	4	140	2	DB01041
Drug	diphenylacetic acid	UGT1A8 UGT1A7	2.23e-04	4	140	2	ctd:C037760
Drug	Lincomycin hydrochloride [859-18-7]; Down 200; 9uM; HL60; HT_HG-U133A	PAPPA2 L2HGDH ZNF276 MYH14 KCTD20 CPNE7 WDTC1	2.29e-04	198	140	7	2380_DN
Drug	Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A	VPS33A MYH14 ZNF45 SCAPER FGFR2 PALS2 WDTC1	2.29e-04	198	140	7	2786_DN
Drug	Meticrane [1084-65-7]; Up 200; 14.6uM; MCF7; HT_HG-U133A	GALNT3 LAMA3 APP SCAPER TREM1 DMTN CPNE7	2.29e-04	198	140	7	5984_UP
Drug	2-propylpentanoic acid; Down 200; 500uM; PC3; HT_HG-U133A	PAPPA2 PHF20 ANK3 SMC1A NFKB2 SCAPER TBCEL	2.29e-04	198	140	7	4464_DN
Drug	Estropipate [7280-37-7]; Up 200; 9.2uM; PC3; HT_HG-U133A	CRHR2 CEMIP ZNF276 MYH14 CEP152 CNGA1 KDM4B	2.29e-04	198	140	7	4472_UP
Drug	cis-4,7,10,13,16,19-Docosahexaenoic acid ethyl ester; Down 200; 100uM; MCF7; HT_HG-U133A_EA	KMT2B L2HGDH SUV39H2 ZNF45 KCTD20 FGFR2 DMTN	2.29e-04	198	140	7	881_DN
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; HL60; HT_HG-U133A	VPS33A MFSD6 SLC7A2 ZNF276 NFKB2 FGFR2 CPNE7	2.29e-04	198	140	7	2138_UP
Disease	N-acetyl-4-chlorophenylalanine measurement	UGT1A8 UGT1A7 UGT1A9	9.30e-07	5	135	3	EFO_0801060
Disease	5-hydroxyindole sulfate measurement	UGT1A8 UGT1A7 UGT1A9	9.30e-07	5	135	3	EFO_0800085
Disease	nuclear receptor subfamily 1 group D member 2 measurement	UGT1A8 UGT1A7 UGT1A9	9.30e-07	5	135	3	EFO_0801853
Disease	X-21339 measurement	UGT1A8 UGT1A7 UGT1A9	3.23e-06	7	135	3	EFO_0800808
Disease	X-11793--oxidized bilirubin measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0021260
Disease	Succinimide measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0022118
Disease	X-11530 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0021249
Disease	sulfate of piperine metabolite C16H19NO3 (2) measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0801034
Disease	cholelithiasis, bilirubin measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0004570, EFO_0004799
Disease	X-11522 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0800696
Disease	X-10458 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0800692
Disease	X-24849 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0800909
Disease	serum N-desmethylclozapine measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0600043
Disease	plasma clozapine measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0600038
Disease	membrane-associated progesterone receptor component 1 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0802740
Disease	X-16946 measurement	UGT1A8 UGT1A7 UGT1A9	5.16e-06	8	135	3	EFO_0800766
Disease	urate measurement, spine bone mineral density	PAPPA2 UGT1A8 UGT1A7 UGT1A9 CPNE4	7.02e-06	58	135	5	EFO_0004531, EFO_0007701
Disease	X-11442 measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0021236
Disease	X-11441 measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0021235
Disease	circulating cell free DNA measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0004739
Disease	sulfate of piperine metabolite C18H21NO3 (3) measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0801037
Disease	sulfate of piperine metabolite C18H21NO3 (1) measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0801036
Disease	X-11880 measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0800698
Disease	protein-tyrosine kinase 6 measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0020691
Disease	testis-specific chromodomain protein Y 1 measurement	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0802127
Disease	bilirubin measurement, response to xenobiotic stimulus	UGT1A8 UGT1A7 UGT1A9	7.71e-06	9	135	3	EFO_0004570, GO_0009410
Disease	response to dolutegravir	UGT1A8 UGT1A7 UGT1A9 PCDH10	1.05e-05	30	135	4	EFO_0600017
Disease	bilirubin measurement, response to tenofovir	UGT1A8 UGT1A7 UGT1A9	1.10e-05	10	135	3	EFO_0004570, EFO_0009279
Disease	X-21448 measurement	UGT1A8 UGT1A7 UGT1A9	1.10e-05	10	135	3	EFO_0800816
Disease	UDP-glucuronosyltransferase 1-6 measurement	UGT1A8 UGT1A7 UGT1A9	1.10e-05	10	135	3	EFO_0802185
Disease	X-23974 measurement	UGT1A8 UGT1A7 UGT1A9	1.10e-05	10	135	3	EFO_0800867
Disease	pregnenetriol sulfate measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0800586
Disease	plasma N-desmethylclozapine measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0600039
Disease	histidine betaine (hercynine) measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0800972
Disease	X-21796 measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0800825
Disease	insomnia, bilirubin measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0004570, EFO_0004698
Disease	aldosterone measurement	UGT1A8 UGT1A7 UGT1A9	1.50e-05	11	135	3	EFO_0010219
Disease	p-cresol glucuronide measurement	UGT1A8 UGT1A7 UGT1A9	2.00e-05	12	135	3	EFO_0800079
Disease	biliverdin measurement	UGT1A8 UGT1A7 UGT1A9	2.00e-05	12	135	3	EFO_0021033
Disease	pregnenetriol disulfate measurement	UGT1A8 UGT1A7 UGT1A9	2.59e-05	13	135	3	EFO_0800587
Disease	X-24588 measurement	UGT1A8 UGT1A9 ACOT2	2.59e-05	13	135	3	EFO_0800898
Disease	retinol dehydrogenase 16 measurement	UGT1A8 UGT1A7 UGT1A9	2.59e-05	13	135	3	EFO_0802007
Disease	Intellectual Disability	FARSB L2HGDH UROC1 BCL11A SACS SCAPER PRKCG FGFR2 MED23 DYNC1H1	4.21e-05	447	135	10	C3714756
Disease	Profound Mental Retardation	L2HGDH UROC1 SCAPER PRKCG FGFR2 DYNC1H1	4.48e-05	139	135	6	C0020796
Disease	Mental Retardation, Psychosocial	L2HGDH UROC1 SCAPER PRKCG FGFR2 DYNC1H1	4.48e-05	139	135	6	C0025363
Disease	Mental deficiency	L2HGDH UROC1 SCAPER PRKCG FGFR2 DYNC1H1	4.48e-05	139	135	6	C0917816
Disease	schizophrenia (is_marker_for)	VWF ANK3 MAP2 SETDB1	4.94e-05	44	135	4	DOID:5419 (is_marker_for)
Disease	low density lipoprotein cholesterol measurement, body fat percentage	UGT1A8 UGT1A7 UGT1A9	6.08e-05	17	135	3	EFO_0004611, EFO_0007800
Disease	X-21441 measurement	UGT1A8 UGT1A7 UGT1A9	6.08e-05	17	135	3	EFO_0800814
Disease	indole-3-carboxylate measurement	UGT1A8 UGT1A9	6.21e-05	3	135	2	EFO_0800043
Disease	blood 4-oxo-retinoic acid measurement	UGT1A8 UGT1A9	6.21e-05	3	135	2	EFO_0022216
Disease	angiopoietin-related protein 1 measurement	UGT1A8 UGT1A7 UGT1A9	7.27e-05	18	135	3	EFO_0801382
Disease	tissue factor measurement	UGT1A8 UGT1A7 UGT1A9	1.17e-04	21	135	3	EFO_0010623
Disease	Lung Diseases, Interstitial	SFTPC FARSB	1.24e-04	4	135	2	C0206062
Disease	Interstitial lung disease 2	SFTPC MUC5B	1.24e-04	4	135	2	cv:C5561926
Disease	INTERSTITIAL LUNG DISEASE 2	SFTPC MUC5B	1.24e-04	4	135	2	178500
Disease	Anhedonia	ANK3 CRHR2 SETDB1	1.77e-04	24	135	3	C0178417
Disease	neuroblastoma, cutaneous melanoma	UGT1A8 UGT1A7 UGT1A9	2.82e-04	28	135	3	EFO_0000389, EFO_0000621
Disease	3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-CMPFP) measurement	UGT1A8 UGT1A9	3.08e-04	6	135	2	EFO_0800566
Disease	Diffuse interstitial pulmonary fibrosis	SFTPC MUC5B	3.08e-04	6	135	2	cv:C0085786
Disease	xeroderma pigmentosum (implicated_via_orthology)	XPC DDB1	3.08e-04	6	135	2	DOID:0050427 (implicated_via_orthology)
Disease	xanthurenate measurement	UGT1A8 UGT1A7 UGT1A9	3.14e-04	29	135	3	EFO_0010551
Disease	Adenocarcinoma of lung (disorder)	SFTPC XPC MSH3 BAP1 FASTK FGFR2	3.83e-04	206	135	6	C0152013
Disease	Head and Neck Neoplasms	ERBB3 BAP1 FGFR2	4.62e-04	33	135	3	C0018671
Disease	neurodegenerative disease (implicated_via_orthology)	BCL11A NFKB1 NFKB2 SCNN1A DYNC1H1	5.55e-04	145	135	5	DOID:1289 (implicated_via_orthology)
Disease	Congenital Hydrocephalus	WDR81 HYDIN	5.71e-04	8	135	2	C0020256
Disease	mesangial proliferative glomerulonephritis (biomarker_via_orthology)	VWF FBN1	5.71e-04	8	135	2	DOID:4783 (biomarker_via_orthology)
Disease	Aqueductal Stenosis	MYH10 HYDIN	5.71e-04	8	135	2	C2936786
Disease	thyroxine measurement	UGT1A8 UGT1A7 LAMA3 UGT1A9	5.82e-04	83	135	4	EFO_0005130
Disease	type 2 diabetes mellitus (biomarker_via_orthology)	UGT1A8 UGT1A7 SMC1A UGT1A9 FBN1	5.91e-04	147	135	5	DOID:9352 (biomarker_via_orthology)
Disease	vitamin D deficiency	UGT1A8 UGT1A7 UGT1A9	6.49e-04	37	135	3	EFO_0003762
Disease	mitral valve prolapse (is_implicated_in)	FLNA FBN1	7.32e-04	9	135	2	DOID:988 (is_implicated_in)
Disease	opportunistic bacterial infectious disease (implicated_via_orthology)	NFKB1 NFKB2	7.32e-04	9	135	2	DOID:0050340 (implicated_via_orthology)
Disease	prostate cancer (is_marker_for)	ERBB3 KMT2B SETDB1 FGFR2 KDM4B	7.73e-04	156	135	5	DOID:10283 (is_marker_for)
Disease	indoleacetate measurement	UGT1A8 UGT1A9	9.13e-04	10	135	2	EFO_0021015
Disease	Head and Neck Carcinoma	ERBB3 FGFR2	9.13e-04	10	135	2	C3887461
Disease	aortic measurement	MYH10 DCDC1 CRHR2 FBN1 HMCN1 ADAMTS18	1.08e-03	251	135	6	EFO_0020865
Disease	Malignant Head and Neck Neoplasm	ERBB3 BAP1 FGFR2	1.08e-03	44	135	3	C0278996
Disease	Immunoglobulin Deficiency, Late-Onset	NFKB1 NFKB2	1.11e-03	11	135	2	C2936665
Disease	Acquired Hypogammaglobulinemia	NFKB1 NFKB2	1.11e-03	11	135	2	C2936664
Disease	visual epilepsy (is_implicated_in)	L2HGDH APP	1.11e-03	11	135	2	DOID:11832 (is_implicated_in)
Disease	craniosynostosis (is_implicated_in)	FLNA FGFR2	1.33e-03	12	135	2	DOID:2340 (is_implicated_in)
Disease	Dental enamel hypoplasia	MYH14 SCAPER	1.33e-03	12	135	2	EFO_1001304
Disease	vitamin D measurement, COVID-19	UGT1A8 UGT1A7 UGT1A9	1.48e-03	49	135	3	EFO_0004631, MONDO_0100096
Disease	susceptibility to measles measurement	PAPPA2 MYO1E HUNK	1.48e-03	49	135	3	EFO_0008414
Disease	Common variable immunodeficiency	NFKB1 NFKB2	1.57e-03	13	135	2	cv:C0009447
Disease	Hamman-Rich syndrome	SFTPC MUC5B	1.82e-03	14	135	2	C0085786
Disease	parental longevity	SPOCK1 BCL11A CEMIP SUSD1 NEK5 PRICKLE2 CSMD1 LPAL2	2.03e-03	494	135	8	EFO_0007796
Disease	Common Variable Immunodeficiency	NFKB1 NFKB2	2.10e-03	15	135	2	C0009447
Disease	Benign neoplasm of stomach	ERBB3 FGFR2	2.70e-03	17	135	2	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	ERBB3 FGFR2	2.70e-03	17	135	2	C0496905
Disease	phosphoglyceric acid measurement	SPOCK1 SUSD1	2.70e-03	17	135	2	EFO_0010523
Disease	Carcinoma in situ of stomach	ERBB3 FGFR2	2.70e-03	17	135	2	C0154060
Disease	autosomal dominant intellectual developmental disorder (is_implicated_in)	KMT2B KDM4B	2.70e-03	17	135	2	DOID:0060307 (is_implicated_in)
Disease	ischemia (implicated_via_orthology)	CRHR2 SCNN1A	2.70e-03	17	135	2	DOID:326 (implicated_via_orthology)
Disease	Usual Interstitial Pneumonia	SFTPC MUC5B	3.38e-03	19	135	2	C4721509
Disease	Hamman-Rich Disease	SFTPC MUC5B	3.38e-03	19	135	2	C4721508
Disease	anorectal malformation	MUC5B UROC1	3.38e-03	19	135	2	MONDO_0019938
Disease	apolipoprotein B measurement	DNAJC13 UGT1A8 UGT1A7 WDR81 UGT1A9 CLCC1 LPAL2 HYDIN DMTN	3.53e-03	663	135	9	EFO_0004615
Disease	coagulation factor measurement	VWF CFHR4	3.74e-03	20	135	2	EFO_0004634

Protein segments in the cluster

Peptide	Gene	Start	Entry
EDSGLYQCVIYQPPK	TREM1	106	Q9NP99
PKCNYVVDNIDHLYP	COP1	171	Q8NHY2
AKGPIYKYPDVQNEC	ERBB3	596	P21860
GPSCQGLEPYNKVTY	CEP152	181	O94986
KLAYQAYELQNCPDP	CSMD1	2076	Q96PZ7
KEGILQYCQEVYPEL	APP	66	P05067
NTENPPGCYRYAEDK	AFM	386	P43652
GVKLENYYIQPICTP	ARSI	81	Q5FYB1
PLKCGQPQEVLVDYY	A2ML1	461	A8K2U0
EIYDLQSKCQGPVYG	BAP1	31	Q92560
KPQIICYPETGHYIE	ACOT2	411	P49753
NEIPYPIKDVVLCYG	LVRN	816	Q6Q4G3
KLLCSVIPQAPQYYD	ANKRD12	1851	Q6UB98
ILRYQPGLSYDQPKC	SLC7A2	431	P52569
YPGYIPKPRQDCNAV	CEMIP	656	Q8WUJ3
YPDKLPGQIYDADTQ	ADAMTS18	506	Q8TE60
PKSQRYAYVVDACQP	MUC5B	696	Q9HC84
PGLEYCEVQRDPYSN	RBM45	271	Q8IUH3
PGFQPQDESLVYLCY	NOMO3	256	P69849
EGYKLSLEPLPCYQL	NUDCD1	21	Q96RS6
EKYRQDLTVPPGYCT	FASTK	416	Q14296
KYQISQPEVYVAAPG	FGFR2	41	P21802
YPPVCELEKNYSHQV	MSH3	1011	P20585
SVIKEENIDQPGYCY	DCDC1	1296	M0R2J8
PGFQPQDESLVYLCY	NOMO2	256	Q5JPE7
QYCYELAPDQGLQPA	LIN9	411	Q5TKA1
GKVCQRPENNYYFPD	LAMA3	711	Q16787
NQTHYIIPKGECLPY	GNPTAB	551	Q3T906
EKCYLVKGNIYPVPD	L2HGDH	291	Q9H9P8
LQFLCKESGLEYYPP	LRSAM1	201	Q6UWE0
YYKTGIINCPDGISI	KCTD20	181	Q7Z5Y7
VKLENYYVQPICTPS	ARSJ	111	Q5FYB0
EYAPQGICKDEPSSY	BCL11A	156	Q9H165
GERQLYCYEVVPQQP	CORO7	281	P57737
FCVVINPYKQLPIYT	MYH14	141	Q7Z406
GTPYYLSPEICQNKP	NEK5	166	Q6P3R8
QIQSPYLPIYFGNVC	MED23	946	Q9ULK4
PGFQPQDESLVYLCY	NOMO1	256	Q15155
ERPCPEYFNGVKYNT	CRHR2	61	Q13324
IKYYAELCAPPGNSD	PGM2	566	Q96G03
YPYCQALQTEKEAPI	KDM4B	691	O94953
PRCTQLYEKGNYCPI	KMT2B	1326	Q9UMN6
CGTPDYIAPEIIAYQ	PRKCG	516	P05129
PYPQYLAVIKAQISC	MED29	156	Q9NX70
YVCGQIRYPVPEESQ	PCDHGC4	26	Q9Y5F7
SPVYQVYVQAKDLGP	PCDH10	321	Q9P2E7
DGKGCKPPEYRNYQI	MFSD6	356	Q6ZSS7
TLPCYVQGYPEPTIK	HMCN1	811	Q96RW7
PICYYSDDHGPIKNV	PTPRQ	1816	Q9UMZ3
QLYFACLPEEKVPYV	PRICKLE1	46	Q96MT3
PEQVHQYYSCLPEEK	PRICKLE2	46	Q7Z3G6
EYCTVQNIPFPKYEL	PLA2G4E	741	Q3MJ16
YNPYNDNLIPCKEAG	PALS2	226	Q9NZW5
IVDCGIYTPKGYLDQ	PAPPA2	1176	Q9BXP8
EYPQDYLNCSEIPKV	PXDNL	1276	A1KZ92
QEITVPLCKGIGYNY	FZD8	36	Q9H461
TPKDQGYYRCVAANP	IGSF10	636	Q6WRI0
QEQVLKVYYLPGVPE	HYDIN	1451	Q4G0P3
RGICTYPYICQDPKV	HYDIN	2786	Q4G0P3
VANIYREVPCKTPYT	HYDIN	4731	Q4G0P3
VLPKVEYQACYGVEA	ICE2	771	Q659A1
LNPDPNEIKSYCYVS	IDI1	161	Q13907
KDFLSYLCPVNAYPN	DCLRE1C	326	Q96SD1
CKYDGIPPKTQDSVY	DCDC2C	251	A8MYV0
IPGSPLQFYVDYVNC	FLNA	1851	P21333
YCPTEPGNYIINIKF	FLNA	2106	P21333
YRCICPPGYSLQNEK	FBN1	1996	P35555
PCLQGYYTAAELKPV	GALNT3	96	Q14435
EAYQSCLPKLQLYGP	CPNE4	396	Q96A23
EAYQNCLPRVQLYGP	CPNE7	471	Q9UBL6
NENYTGKVPCNVTYP	HUNK	321	P57058
EGKPIYVDCYGNLAP	ANK3	1361	Q12955
IYILNEETQYNCKPG	CFHR4	106	Q92496
YCPIPIINYPQLENE	DNAJC13	1236	O75165
LNPPIEECRYKLYQE	DYNC1H1	971	Q14204
KNYPGTYPNHTVCEK	DCBLD1	56	Q8N8Z6
PTYCLEYKNVPTDIN	ENPP6	151	Q6UWR7
YVCNKEEYGFLPVPL	COLGALT1	281	Q8NBJ5
GNSLPCVLEQKIYPY	DMTN	331	Q08495
TICTLNPYRYPEIKE	SCNN1A	131	P37088
QPYQPKGKCLGSQDY	SCAPER	1361	Q9BY12
GCQLPLTVEAPYSYN	SACS	1626	Q9NZJ4
CGKPVVNVSYRPAYD	DUSP5	161	Q16690
RECKYDLPPYAANIV	IPO13	556	O94829
PLYESPRKICYQEVS	DDB1	716	Q16531
FCVVINPYKNLPIYS	MYH10	121	P35580
YQQLLIAYKPAPGTC	SFTPC	106	P11686
YYFENPTNPELCQKK	PANK1	386	Q8TE04
ENVPEKYTCYVCQDP	PHF20	686	Q9BVI0
ENYPYQLGEISSLPC	SPAG8	456	Q99932
HQEGKAPQCLLYYEP	TRGV1	56	A0A0A0MS02
QDYNGLCDPYVILKL	FER1L5	1501	A0AVI2
KYPNDGLISNYCRNP	LPAL2	66	Q16609
YPQALVCYQEGIDLL	MITD1	31	Q8WV92
CIDFSPYNIKYQPKV	RIF1	766	Q5UIP0
QVLAKDCYPETYVPT	RND1	31	Q92730
DPQKQLIIEDPYYGN	ACP1	121	P24666
YSNVYCPTPKVQDLV	NPRL2	241	Q8WTW4
NKPLYPVIYDSNGVV	FARSB	216	Q9NSD9
PNSGYQYKRLEECLP	SETDB1	761	Q15047
LPCAKALYNYEGKEP	SH3RF1	136	Q7Z6J0
KICDGIFYTPQYLNP	PRKAA1	236	Q13131
LQPQVYSPGDYICKK	CNGA1	491	P29973
DDPCQKYYELLLVNP	CLCC1	276	Q96S66
RQIYDPKYCPQGTVA	CNN2	266	Q99439
KNLCVELYPAPRESY	PRAMEF6	406	Q5VXH4
CDRQKPLPDGAAQYY	WDTC1	236	Q8N5D0
ACQLTYPLHTYPKEE	TMEM59	51	Q9BXS4
RSYEPGEPNCRIYVK	RNPC3	411	Q96LT9
LKYLFPGECQYVLVQ	VWF	881	P04275
KLVDDNVEYCIPAPY	TIAM2	856	Q8IVF5
VIKYYPEQEPQLLSG	TRAPPC12	571	Q8WVT3
LLAEYGSYNISQPCP	TMPRSS7	471	Q7RTY8
RAYPIEQYPCQTKVA	UROC1	86	Q96N76
PEVCLALYPGTNYTV	SUSD1	356	Q6UWL2
YINEYKPAPGISLVN	SUV39H2	171	Q9H5I1
QSLGDPLYYGKIQPC	SUPT20H	356	Q8NEM7
PLYYGKIQPCKADEE	SUPT20H	361	Q8NEM7
KNLCVELYPAPRESY	PRAMEF5	406	Q5TYX0
EREELPTIYKCPYQG	ZNF276	426	Q8N554
PSEINAIYLDKYEPC	SPOCK1	266	Q08629
PYLDGINYNCVAPGK	SMC1A	1106	Q14683
LLYPCGQQDQLPDYL	SH2D4A	436	Q9H788
DVNLPCTYDPLQGYT	VSIG4	36	Q9Y279
YLEEGAQCPAPLSYV	UGT1A9	176	O60656
DLGYCVFNKYTVPLP	MAP2	866	P11137
GPAPCPTQTYVKYQV	XP32	46	Q5T750
YSQAIEALPPDKYGQ	TTK	91	P33981
RGPECVQYLQQEYLP	XPOT	911	O43592
DEIYGIQNSYVKLPP	VPS33A	251	Q96AX1
VVGQPLTCYKYATKP	XPC	551	Q01831
ILCGQISQYNKDVPY	PTGR2	251	Q8N8N7
VPTGENPYKYEECGR	ZNF45	241	Q02386
QVLCEKYSPENFPYR	TBCEL	11	Q5QJ74
YLLKPLIGAYESPCQ	WDR81	961	Q562E7
GTDPVSLRNYPYKIC	ZNF248	126	Q8NDW4
KGCPYIGDNYQTQLI	ZP4	386	Q12836
YLEEGAQCPAPLSYV	UGT1A7	176	Q9HAW7
CRLYTQFQEPYLKDP	TM6SF1	246	Q9BZW5
LQQCSTPDGKYYRPD	UBASH3A	416	P57075
YLEEGAQCPAPLSYV	UGT1A8	176	Q9HAW9
IINKEGYLYEDSPQP	ZNF302	161	Q9NR11
VKLRYGNKPEDCPYL	AGL	491	P35573
PQVPQCKALYAYDAQ	MYO1E	1051	Q12965
QKEGAPVTLPYQVYF	MYO7B	1876	Q6PIF6
YPQVKICNYVGPAKV	NFKB1	81	P19838
TYPTVKICNYEGPAK	NFKB2	76	Q00653